AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Carl Zeiss Meditec AG

Earnings Release Jan 19, 2021

74_rns_2021-01-19_21427af4-6e3d-4875-918c-d8d597dbb62d.html

Earnings Release

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 19 January 2021 09:54

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

Carl Zeiss Meditec AG / Key word(s): Quarter Results

Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21

19-Jan-2021 / 09:54 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG achieves increase in profit in first quarter 2020/21
Jena, January 19, 2021



Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 368.9 million in the first quarter of fiscal year 2020/21 (previous year: EUR 369.7 million). This corresponds to a revenue development of -0.2% vs. the past year (after adjustment for currency effects [1] : +2.6%).



Earnings before interest and taxes (EBIT) [2] amounted to EUR 73.4 million in the first quarter of fiscal year 2020/21 (previous year: EUR 56.8 million). EBIT margin (EBIT / revenue) was 19.9% (previous year 15.4%). EBIT development benefitted in part from lower sales and marketing expenses compared to the previous year’s period. In addition, EBIT includes a one-time gain from the sale of a property in the amount of around EUR 2.4 million in the current period.



Earnings per share (EPS) [3] amounted to EUR 0.52 (previous year: EUR 0.43).



Full results for the first quarter 2020/21 will be published on February 8, 2021.



During the further course of fiscal year 2020/21, the company expects the recovery in revenue and EBIT to continue compared to the previous year, which had seen a marked impact from the COVID-19 pandemic.

Contact for investors and press

Sebastian Frericks

Head of Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: [email protected]

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.

[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).


19-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: [email protected]
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1161506
End of Announcement DGAP News Service

show this

Talk to a Data Expert

Have a question? We'll get back to you promptly.